Leading the Way in Life Science Technologies

GEN Exclusives

More »

February 1, Vol. 29, No. 3

  • Feature Articles

    • Improving Delivery of RNAi Drugs
    • Nina Flanagan
    • Hailed as the breakthrough of the year in 2002 by Science , RNAi still holds promise as a powerful, novel therapeutic for a wide variety of diseases and viruses Its exquisite ability to selectively silence any gene taunts scientists still ... more »
    • GEN’s Annual Wall Street Roundup
    • Survival of the fittest has governed life on Earth since the beginning of time, but it was first defined only 150 years ago by Charles Darwin Today, it couldn’t be any more obviously at play, with economic turmoil necessitating a ... more »
    • Alternatives to Mammalian Expression
    • K. John Morrow Jr.
    • As the market for recombinant proteins continues to skyrocket, biotechs are exploiting a range of options to deal with multiple possibilities At last month’s CHI “Peptalk” conference, participants explored advances in a number of different expression systems, including bacteria, yeast, ... more »
    • Targeting Post-Translational Modifications
    • Angelo DePalma
    • Post-translational modifications (PTM)—chemical transformations that occur after a protein’s translation from RNA—include numerous changes, some well known and others quite obscure Modifications based on the addition of molecules or functional groups are the most apparent and probably the most significant ... more »
    • Raising Molecular Imaging to Higher Level
    • Gail Dutton
    • In vivo molecular imaging can dramatically increase the efficiency of drug development and diagnostics, characterizing target engagement, pharmacokinetics, and pharmacodynamics, according to researchers at Cambridge Healthtech’s recent “In Vivo Molecular Imaging” meeting Some of the newer in vivo molecular imaging ... more »
    • Strategies to Overcome Blood-Brain Barrier
    • Allan Haberman
    • Central nervous system (CNS) diseases are a major focus of the pharmaceutical industry, with CNS drugs representing some of its most successful products These include Pfizer’s Zoloft, Eli Lilly’s Cymbalta, and Abilify from Bristol-Myers Squibb and Otsuka ... more »
    • Chinese Outsourcing Nears Full Service
    • Jim J. Zhang, Ph.D.
    • The Chinese outsourcing industry is playing an increasingly important role in today’s global pharmaceutical arena The capabilities of this industry are limited at present, and no China-based service providers are currently able to provide totally integrated service This situation is ... more »
  • Columns

    • GEN's Interview with Dr. Francisco J. Ayala
    • Francisco J Ayala, PhD, is university professor and Donald Bren professor of biological sciences, ecology & evolutionary biology, School of Biological Sciences, at the University of California, Irvine Dr Ayala is one of the world’s foremost evolutionary geneticists, whose academic ... more »
    • CytImmune Banks on Gold Nanoparticles
    • Ilene Schneider
    • CytImmune Sciences, a clinical-stage biopharmaceutical company based in Rockville, MD, is attempting to use nanotechnology to change the way we treat cancer, according to cofounder, president, and CEO Lawrence Tamarkin, PhD “Our technology is designed to treat cancer medically first ... more »
    • Visualizing Signal Transduction Pathways
    • Simon Fredriksson
    • A wealth of tools are available today to study cell-signaling mechanisms When it comes to actually quantifying transient protein-protein interactions within a single native cell, however, adequate tools are missing Currently used techniques lyse significant quantities of the studied cells ... more »
    • Promega's Protein Purification Project
    • Promega recently introduced a couple of new tools to make life easier for recombinant protein aficionados HaloTag, despite a name that conjures up cherubim and seraphim, is a solid, down-to-earth product According to Kate Qin Zhao, PhD, a senior research ... more »
    • Novozymes Exploits a Venerable Bioproduction Too...
    • Novozymes, formerly part of NovoNordisk, bases much of its contract manufacturing capability on yeast-based expression, which it believes to be the gold standard in microbial protein expression, according to Dermot Pearson, marketing director NovoNordisk’s experiences in biomanufacturing have enabled Novozymes ... more »
  • Tutorials

    • Accelerating Protease Drug Development
    • NIcholas Ede
    • Proteases are involved in the regulation of a wide variety of essential physiological processes, and their dysregulation has been implicated in a number of disorders including cardiovascular disease, rheumatoid arthritis, Alzheimer’s disease, and cancer Hence, proteases and their substrates are ... more »
    • Simplification of Kinase Binding Assays
    • Steven Riddle
    • Over the past decade, small molecule kinase inhibitors have emerged as promising therapeutics, particularly in oncology Through data that has emerged during this period, it has become increasingly apparent that small molecule inhibitors interact differently with the various conformational and ... more »
    • Three-Dimensional Cultivation of Cells
    • Hans Hoffmeister
    • Cell cultivation is one of the most common techniques used in modern life science and medical research The predominant method grows cells as mono-layers in plastic dishes Much of the knowledge about contemporary cell biology has been generated from such ... more »